NKMAX CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,020 KRW | +9.54% |
|
-.--% | -67.58% |
| Apr. 17 | NKMAX CO., Ltd. cancelled the transaction announced on October 20, 2023 | CI |
| Apr. 16 | NKMAX CO., Ltd.(KOSDAQ:A182400) dropped from S&P Global BMI Index | CI |
| Sales 2022 | 11.26B 8.2M | Sales 2023 | 10.77B 7.84M | Capitalization | 516B 376M |
|---|---|---|---|---|---|
| Net income 2022 | -53.5B -38.95M | Net income 2023 | 5.26B 3.83M | EV / Sales 2022 | 52.2 x |
| Net Debt 2022 | 43.28B 31.51M | Net Debt 2023 | 51.52B 37.51M | EV / Sales 2023 | 52.7 x |
| P/E ratio 2022 |
-10.1
x | P/E ratio 2023 |
104
x | Employees | 134 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 87.98% |
More Fundamentals
* Assessed data
More news
| 1 day | +9.54% | ||
| 1 month | +9.54% | ||
| 3 months | -45.26% | ||
| 6 months | -64.56% | ||
| Current year | -67.58% |
Current year
1 550.00
8 200.00
1 year
1 550.008 205.00
3 years
1 550.0016 250.00
5 years
1 550.0016 250.00
10 years
1 550.0016 250.00
| Managers | Title | Age | Since |
|---|---|---|---|
Sang-Woo Park
CEO | Chief Executive Officer | 55 | 02-01-13 |
Jun-Yong Song
DFI | Director of Finance/CFO | 57 | - |
Yong-Hwan Cho
COO | Chief Operating Officer | 52 | 14-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sang-Woo Park
CEO | Chief Executive Officer | 55 | 02-01-13 |
Yong-Man Kim
BRD | Director/Board Member | 58 | 19-05-12 |
Kang-Yong Pierre
SAM | Sales & Marketing | 52 | 09-07-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.07% | 2 M€ | -.--% | ||
| 0.03% | 7 M€ | -.--% | - | |
| 0.01% | 4 M€ | -4.41% | - | |
| 0.00% | 117 M€ | +0.68% | - |
NKMAX Co., Ltd., formerly ATGen, is a Korea-based company principally engaged in the research, development, manufacturing and supply of biological products. The Company is involved in the production and sale of recombinant proteins, monoclonal antibodies, NK cell activity test kits, cell therapy products, and in the provision of other related services. The NK cell activity test kits are provided under the name of NK Vue. The Company distributes its products within domestic market and to overseas markets.
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -67.58% | 126M | |
| -1.51% | 104B | |
| +3.22% | 97.42B | |
| +0.47% | 22.2B | |
| -16.53% | 21.23B | |
| -8.03% | 18.33B | |
| -42.33% | 16.35B | |
| -20.09% | 15.06B | |
| +5.47% | 13.98B | |
| +28.85% | 11.66B |
- Stock Market
- Equities
- A182400 Stock
